Australia's most trusted
source of pharma news
Posted 19 June 2024 AM
Some of the world's richest pharmas are earning the majority of their revenue from drugs that are over 10 years old and heading for patent expiry, but new analysis has exposed which companies have "freshened" their portfolios to replace that income when it disappears.
Evaluate's 2024 Freshness Index: Who Needs to Freshen Up? looked at the Top 10 companies by revenue from both prescription and over-the-counter drugs in 2023 to find which pharma's revenues are the closest to the cliff and which companies need to freshen up.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.